Finance

Jun 21 2020

#Ascendis #pharma-Ascendis pharma

Ascendis pharma All US Exchanges Volume Percent Advances Stocks: 15 20 minute delay (Cboe BZX is real-time), ET. Volume reflects consolidated markets. Futures and Forex: 10 or 15 minute delay, CT. © 2020 Barchart.com, Inc. All Rights Reserved. Most Active pages spotlight stocks that show significant movement in regards to the volume of trading activity. Volume Advances “Volume Percent Advance” is today’s Volume divided by the 20-Day Average Volume. Stocks are listed in descending order of the Volume Percent Advance on this page. What’s Included For U.S. Markets: The initial page displayed is for “All US Exchanges” (includes only NYSE, …

Jun 20 2020

#Ascendis #pharma-Ascendis pharma

Ascendis pharma UNITED THERAPEUTICS CORP – 10-Q – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Edgar Glimpses Via Acquire Media NewsEdge) The following discussion should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2013, and the consolidated financial statements and accompanying notes included in Part I, Item I of this Quarterly Report on Form 10-Q. The following discussion contains forward-looking statements made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, …

Jun 16 2020

#Ascendis #pharma-Ascendis pharma

Ascendis pharma Regulatory News Related Topics: Topics also related to Regulatory News Sections: Indians light lamps to heed Modi’s call for coronavirus comradeship MUMBAI/DHAKA Millions of Indians turned off their lights and lit up balconies and doorsteps with lamps, candles and flashlights on Sunday, in response to Prime Minister Narendra Modi’s appeal to “challenge the darkness” spread by the coronavirus crisis. India curbs diagnostic testing kit exports as virus spreads NEW DELHI/DHAKA India is restricting the export of most diagnostic testing kits, as coronavirus cases in the South Asian nation topped 3,350 on Sunday despite a three-week nationwide lockdown to …

Jun 4 2020

#Ascendis #pharma-Ascendis pharma

Ascendis pharma UTHR, Ascendis collaborate for self-injectable PAH medication United Therapeutics (UTHR) and Ascendis Pharma have collaborated to apply Ascendis’ TransCon technology platform to UTHR’s treprostinil molecule. Subscribe to our email newsletter The partnership will focus on developing self-injectable treprostinil molecule, the active ingredient in Remodulin (treprostinil) injection, for pulmonary arterial hypertension (PAH). The TransCon technology platform is expected enhance the delivery profile of treprostinil by providing a controlled, long-acting release of carrier-link product. United Therapeutics chairman and chief executive officer Martine Rothblatt said, “The potential to bring another novel therapeutic option to PAH patients represents an exciting new opportunity …

Jun 3 2020

#Ascendis #pharma-Ascendis pharma

Ascendis pharma Financial Calendars – Yahoo Finance Apr 05, 2020 – Apr 11, 2020 Companies Like PKS Holdings (ASX:PKS) Can Afford To Invest In Growth Just because a business does not make any money, does not mean that the stock will go down. For example, although. Apple has donated 20 million masks, is working to make 1 million face shields a week, Tim Cook says Amid a nationwide shortage of protective equipment for health-care workers treating coronavirus patients, Apple Inc. has donated more than 20 million face masks worldwide and has started manufacturing 1 million face shields a week, Chief …

May 31 2020

#Ascendis #pharma-Ascendis pharma

Ascendis pharma Vitae Pharmaceuticals Announces Exercise of Underwriters’ Option to Purchase Additional Shares of Initial Public Offering FORT WASHINGTON, Pa., Oct. 27, 2014 (GLOBE NEWSWIRE) — Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical stage biotechnology company, today announced that the underwriters of its previously announced initial public offering (IPO) of common stock have exercised in full their option to purchase 1,031,250 shares of common stock at the IPO price of $8.00 per share, less underwriting discounts. After giving effect to the over-allotment closing, the aggregate net proceeds to Vitae from the IPO, after underwriting discounts and commissions and estimated offering expenses, …

May 23 2020

#Ascendis #pharma-Ascendis pharma

Ascendis pharma UTHR, Ascendis collaborate for self-injectable PAH medication United Therapeutics (UTHR) and Ascendis Pharma have collaborated to apply Ascendis’ TransCon technology platform to UTHR’s treprostinil molecule. Subscribe to our email newsletter The partnership will focus on developing self-injectable treprostinil molecule, the active ingredient in Remodulin (treprostinil) injection, for pulmonary arterial hypertension (PAH). The TransCon technology platform is expected enhance the delivery profile of treprostinil by providing a controlled, long-acting release of carrier-link product. United Therapeutics chairman and chief executive officer Martine Rothblatt said, “The potential to bring another novel therapeutic option to PAH patients represents an exciting new opportunity …

Apr 25 2020

#Ascendis #pharma-Ascendis pharma

Ascendis pharma European VC sees biggest investment quarter since 2001 European companies raised €2.6 billion for 345 deals during the first quarter of 2015 Europe’s venture capital scene was a pretty mixed bag in the first quarter of this year. While the amount invested by VCs rose nicely, the amount raised by those firms fell somewhat ominously. European companies raised €2.6 billion for 345 deals during the first quarter of 2015, according to the 1Q’15 Europe Venture Capital Report from Dow Jones VentureSource, released on Monday. That represents an increase of 41% in the amount raised from the previous quarter. …

Apr 15 2020

#Ascendis #pharma-Ascendis pharma

Ascendis pharma NewStatesman You are browsing in private mode. To enjoy all the benefits of our website LOG IN or Create an Account How Big Pharma keeps you calmer The etymological wizardry of our drugs. Millions of people in this country get up every morning and put something with a funny name in their mouths – in 2009 (the last year figures were available), some 39.1 million prescriptions for antidepressants were written in the UK; and while I believe this indicates a mass hysteria (among doctors and pharmacists as much as their patients and customers), I’m minded to investigate the …

Apr 12 2020

#Ascendis #pharma-Ascendis pharma

Ascendis pharma Ascendis pharma name left most recent information on whereabouts Postdoctoral fellows Dr. Daniel Gottlieb Senior Consultant, Lanxess AG, Leverkusen Dr. Surendra Harkal Team leader, Syngenta, Goa, India Dr. Bhubaneswar Mandal Professor, IIT Guwahati, India Dr. Roman J. Lichtenecker Lecturer (“Oberassistent”), U of Vienna, Austria Dr. Eric Täuscher 2012 Senior Scientist, TU Ilmenau Dr. Cyril Ronco 2013 Associate Professor, U Nice Sophia Antipolis, France PD Dr. Christoph Enzensperger 2016 Research Scientist, SmartDyeLivery, Jena Dr. Claudia Rössler 2018 Frankfurt Doctoral students Dr. Matthias Riedrich Plant manager, BayerCrop Science, Dormagen QA manager, Gilead, Edmonton (CAN) Dr. B ahar Kilitoglu Research Scientist, …

Apartment | Auto | Car | Credit | Insurance | Loan | News | Pharma | Real Estate | Rental | Travel | USA |